Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS [Phase 1, Phase 2]

View source ↗

Summary

A personalized antisense oligonucleotide therapy targeting TARDBP was tested in a single participant with amyotrophic lateral sclerosis in Phase 1/2; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Personalized antisense oligonucleotide therapy (TARDBP-targeted ASO)

Snippet

Sponsor: n-Lorem Foundation | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: COMPLETED